Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement